Strategic partnership Domainex is a Cambridge-based integrated drug discovery CRO with recent high-profile partnerships and leadership changes, presenting a growth trajectory and collaboration opportunities for pharma and biotech partners seeking expanded capabilities.

Targeted capabilities Strengths include medicinal chemistry, fragment screening, computational chemistry, structural biology, and bespoke protein production with fast identification of stable domains, enabling joint programs across early to mid-stage drug discovery.

Efficiency advantage Domainex reports a track record of delivering on average one candidate drug per year for six years and claims 30% time savings versus industry norms, offering supply- and time-efficiency appeals to time-pressed pharmaceutical teams.

Growth momentum Recent leadership appointment and awards, plus expansion of biophysical capabilities and ongoing webinar initiatives, signal an active investment in scale, credibility, and market visibility that can be leveraged in outreach to potential collaborators and investors.

Funding and awards With revenue in the lower single digits and external funding of several million dollars alongside recognized awards (King’s Award for International Trade, Cambridge SME high-growth), Domainex presents as a capable partner for grant-driven collaborations and funded research programs.